Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to show no change in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
LSEG's mean analyst estimate for Quoin Pharmaceuticals Ltd is for a loss of $4.98 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Quoin Pharmaceuticals Ltd is $30.00, about 65.6% above its last closing price of $10.33
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -6.83 | -7.41 | -6.28 | Beat | 15.3 |
Mar. 31 2025 | -6.26 | -6.07 | -6.50 | Missed | -7.1 |
Dec. 31 2024 | -16.10 | -12.25 | Beat | 23.9 | |
Sep. 30 2024 | -16.30 | -17.27 | -16.45 | Beat | 4.7 |
Jun. 30 2024 | -20.98 | -21.35 | -13.65 | Beat | 36.1 |
Mar. 31 2024 | -26.10 | -26.60 | -38.85 | Missed | -46.1 |
Dec. 31 2023 | -81.02 | -72.80 | Beat | 10.2 | |
Sep. 30 2023 | -1.01 hundred | -95.27 | -68.25 | Beat | 28.4 |
This summary was machine generated November 4 at 14:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)